Uploaded August 2026 | Updated September 2026, 3 weeks ago

---

They're the wonder drugs of our age - the GLP-1 inhibitors like Ozempic and Mounjaro - that have revolutionised the treatment of diabetes and obesity worldwide.

Earlier this year the manufacturer of one of those drugs - Mounjaro owner Eli Lilly - walked away from negotiations with Australia's PBS, claiming Australia wasn't offering enough money.

According to Eli Lilly, the PBS is the problem - out of step with modern drug development.

But also part of the story: a Donald Trump executive order forcing US pharmaceutical companies to offer the same price on prescription drugs to Americans as consumers pay in countries like Australia.

7.30’s Sarah Ferguson interviews David Ricks, the CEO of Eli Lilly, the world's first trillion-dollar drug company.

Subscribe: ab.co/3yqPOZ5 Read more here: https://www.abc.net.au/news/2026-08-12/eli-lillyceo-still-looking-to-bring-mounjaro-to-australia/107030066

Welcome to ABC News In-depth, where you'll find our long-form journalism and other videos to help you understand what's going on in the world around you.

Watch more ABC News content ad-free on ABC iview: ab.co/2OB7Mk1

For more from ABC News, click here: ab.co/2kxYCZY

Get breaking news and livestreams from our ABC News channel: youtube.com/user/NewsOnABC
Like ABC News on Facebook: facebook.com/abcnews.au
Follow ABC News on Instagram: instagram.com/abcnews_au
Follow ABC News on Twitter: twitter.com/abcnews

Note: In most cases, our captions are auto-generated.

#ABCNewsIndepth #ABCNewsAustralia